Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
In the extension study, 53% of patients receiving ropeginterferon alfa-2b met the primary end points, compared with 38% of patients receiving hydroxyurea.
Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Patients receiving aspirin and anticoagulation experienced a 3-fold increase in risk for severe hemorrhage compared with patients receiving either treatment alone.
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
EPO level was found to be positively associated with obesity and smoking status, making it an unreliable diagnostic factor in those patients.
